NCT00615758 - Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IV | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

Erlotinib

Erlotinib at the dose of 150 mg orally once a day continually until progression

Trial Locations (5)

401 Military Hospital, Medical Oncology Unit, Athens

Air Forces Military Hospital, Dep of Medical Oncology, Athens

"IASO General Hospital of Athens, 1st Dep of Medical Oncology", Athens

"Sotiria General Hospital, 2nd Dep of Pulmonary Diseases", Athens

"Diabalkaniko Anticancer Hospital of Thessaloniki", Thessaloniki